Bayer to develop PPL's transgenic AAT

Bayer (DAX:BAYG) acquired a worldwide license from PPL Therapeutics (LSE:PTH) to develop transgenically-produced recombinant alpha1-antitrypsin ( AAT) to treat AAT deficiency-related emphysema and cys...